Wang C, McGraw KL, McLemore AF, Komrokji R, Basiorka AA, Al Ali N, Lancet JE, Padron E, Kosmider O, Fontenay M, Fenaux P, List AF, Sallman DA. Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin. haematol [Internet]. 2022Mar.1 [cited 2024Apr.19];107(3):737-9. Available from: https://haematologica.org/article/view/haematol.2021.278855